RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for More than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites

Friday, March 21, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

MERIDIAN, Idaho, March 21 RxElite, Inc.(OTC Bulletin Board: RXEI), a developer, manufacturer, and marketer ofspecialty generic prescription drug products, today announced the signing of amulti-source contract award with Premier, Inc. for the sale of RxElite'sanesthetic gas products, Sevoflurane and Isoflurane. RxElite was awarded thismulti-source contract listing for all classes of trade and the company'sanesthetic gas products are immediately available to all Premier members.Sevoflurane is the most commonly used anesthetic gas in the United States andIsoflurane continues to be widely used in anesthesia practice.

"This contract has delivered significant value to the Premier members thathave already implemented it and we look forward to continuing to drive valuefor all Premier members," stated Jonathan Houssian, CEO of RxElite.

RxElite anesthetic gases are manufactured by Minrad International, Inc., aleader in the innovation of anesthesia. RxElite holds the exclusivedistribution rights for Minrad produced anesthetic gases for the human marketin the United States.

About RxElite, Inc

RxElite, Inc. develops, manufactures, and markets generic prescriptiondrug products in specialty generic markets. These markets include products inthe areas of anesthesia and sterile liquid dose drugs (including respiratoryinhalation drugs, ophthalmics, and injectable drugs).

About Premier, Inc., 2006 Malcolm Baldrige National Quality Awardrecipient -- Serving 1,700 U.S. hospitals and more than 49,000 otherhealthcare sites, the Premier healthcare alliance and its members aretransforming healthcare together. Owned by not-for-profit hospitals, Premieroperates one of the leading healthcare purchasing networks and the nation'smost comprehensive repository of hospital clinical and financial information.A subsidiary operates one of the nation's largest policy-holder owned,hospital professional liability risk-retention groups. A world leader inhelping healthcare providers deliver dramatic improvements in care, Premier isworking with the United Kingdom's National Health Service North West and theCenters for Medicare and Medicaid Services to improve hospital performance.Headquartered in San Diego, Premier has offices in Charlotte, N.C.,Philadelphia, and Washington. For more information, visithttp://www.premierinc.com . Established to improve the health of communities,Premier and its members are transforming healthcare together.

About Minrad International, Inc.

Minrad International, Inc. is an interventional pain management companywith real-time image guidance and anesthesia and analgesia product lines. Thereal-time image guidance products facilitate minimally invasive surgeryespecially for pain management and have broad applications in orthopedics,neurosurgery, and interventional radiology. These devices enable medicalprofessionals to improve the accuracy of interventional procedures and reduceradiation exposure. Minrad International also manufactures and markets genericinhalation anesthetics for use in connection with human and veterinarysurgical procedures. The company is developing a drug/drug delivery system forconscious sedation, which, similar to nitrous oxide in dental surgery,provides a patient with pain relief without loss of consciousness. Additionalinformation can be found at the company's website, http://www.minrad.com .

Safe Harbor Statement

This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 involving known andunknown risks, delays, and uncertainties that may cause our actual results orperformance to differ materially from those expressed or implied by theseforward-looking statements. These risks, delays, and uncertainties include,but are not limited to: risks associated with the uncertainty of futurefinancial results, our reliance

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store